INDICATIONS AND USAGE（适应症）

Non-Small Cell Lung Cancer

IMFINZI is indicated for the treatment of adult patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.

Small Cell Lung Cancer

IMFINZI, in combination with etoposide and either carboplatin or cisplatin, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).

DOSAGE（服用剂量）

The recommended dosage for unresectable stage III NSCLC is as follows:

Patients with a body weight of 30 kg and more: 10 mg/kg every 2 weeks or 1500 mg every 4 weeks or

Patients with a body weight of less than 30 kg: 10 mg/kg every 2 weeks

Until disease progression, unacceptable toxicity, or a maximum of 12 months

The recommended dosage for ES-SCLC is as follows:

Patients with a body weight of 30 kg and more: 1500 mg in combination with chemotherapy* every 3 weeks (21 days) for 4 cycles, followed by 1500 mg every 4 weeks as a single agent or

Patients with a body weight of less than 30 kg: 20 mg/kg in combination with chemotherapy* every 3 weeks (21 days) for 4 cycles, followed by 10 mg/kg every 2 weeks as a single agent

Until disease progression or unacceptable toxicity

*Administer IMFINZI prior to chemotherapy on the same day. When IMFINZI is administered in combination with chemotherapy, refer to the Prescribing Information for etoposide and carboplatin or cisplatin for dosing information.

ADVERSE REACTIONS（不良反应）

Immune-Mediated Adverse Reactions

Infusion-Related Reactions

For full information, please refer to:

https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/8baba4ea-2855-42fa-9bd9-5a7548d4cec3/spl-doc?hl=durvalumab

durvalumabinformation